Vedolizumab 300mg powder for solution for infusion vials
NHS hospitals in England used £153,013,681 of indicative cost of Vedolizumab 300mg powder for solution for infusion vials in the 12 months to April 2026, about 0.6% of all hospital medicines spend. That is down 4.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Vedolizumab 300mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Vedolizumab 300mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Univ Hpl B/Ham Nhs Foundation Trust | £5,473,500 |
| London North West Healthcare Nhs Trust | £4,118,450 |
| Western Sussex Hospitals Nhs Found Trust | £4,102,050 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £3,722,800 |
| Hull And East Yorkshire Hpls Nhs Trust | £3,673,600 |
| University Hospitals Dorset Nhs Ft | £3,646,950 |
| Oxford University Hospitals Nhs Ft | £3,554,700 |
| Sheffield Teaching Hospitals Nhs Trust | £3,487,050 |
| Aintree University Hospital Nhs Ft | £3,296,400 |
| University Hpls Of Leicester Nhs Trust | £3,224,650 |
The primary-care picture
Vedolizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Vedolizumab medicine page.